



Correction: Radiation dosimetry and pharmacokinetics of the tau PET tracer florzolotau (18F) in healthy Japanese subjects

Masaomi Miyamoto¹ · Chio Okuyama² · Shinya Kagawa² · Kuninori Kusano² · Masaaki Takahashi² · Keisuke Takahata³ · Ming-Kuei Jang¹ · Hiroshi Yamauchi^{2,4}

Published online: 7 March 2024
© The Author(s) 2024

**Correction: Annals of Nuclear Medicine (2023)
37:300–309
<https://doi.org/10.1007/s12149-023-01828-x>**

In the sentence beginning ‘The effective dose was...’ in this article [in ‘Abstract’, under the heading ‘Conclusion’], the value ‘3.61 mSv’ should have read ‘3.64 mSv’.

In the sentence beginning ‘Based on the results of this experiment, ...’ in this article [in page 305], the value ‘3.61 mSv’ should have read ‘3.64 mSv’.

In Table 2 of this article, the data in the ‘Right kidney’ headed ‘Mean’, the value ‘0.0610’ should have read ‘0.0160’.

In the sentence beginning ‘The effective dose was...’ in this article [in page 307], the value ‘3.61 mSv’ should have read ‘3.64 mSv’.

In the sentence beginning ‘The effective dose was 19.7 μ Sv/MBq, ...’ in this article [in page 308], the value ‘3.61 mSv’ should have read ‘3.64 mSv’.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s12149-023-01828-x>.

✉ Masaomi Miyamoto
masaomi.miyamoto@aprinoia.com

¹ APRINOIA Therapeutics Inc., Tokyo, Japan

² Shiga Medical Center Research Institute, Moriyama, Japan

³ Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Chiba, Japan

⁴ Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan